Literature DB >> 2992669

Pre-incubation of guinea-pig myenteric plexus with beta-funaltrexamine: discrepancy between binding assays and bioassays.

A D Corbett, H W Kostelitz, A T McKnight, S J Paterson, L E Robson.   

Abstract

The acute effects of beta-funaltrexamine and the effects of pre-incubation with this compound were examined in five in vitro assay tissues and in selective binding assays in homogenates of guinea-pig brain and myenteric plexus. In competitive displacement assays with selective ligands, beta-funaltrexamine had highest affinity for the mu-binding site in the myenteric plexus and brain of guinea-pig. Its affinity for the kappa-site was about 15% of that for the mu-site. Pre-incubation of the assay tissues with beta-funaltrexamine caused an increase in the IC50 values of mu- and delta-receptor agonists but not of kappa-agonists. Although in bioassays on the myenteric plexus-longitudinal muscle preparation of the guinea-pig, the IC50 value of the mu-receptor ligand [D-Ala2, MePhe4, Gly-ol5] enkephalin was increased up to 124 fold, its binding at the mu-site in homogenates of the preparation was not affected by this treatment. These findings indicate that the effects of pre-incubation with beta-funaltrexamine on agonist potency of the mu-receptor ligand are due to an interference with the coupling mechanism between the mu-binding site and the effector system.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2992669      PMCID: PMC1916526          DOI: 10.1111/j.1476-5381.1985.tb10562.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  22 in total

1.  Specificity of opioids towards the mu-, delta- and epsilon-opiate receptors.

Authors:  M Wüster; R Schulz; A Herz
Journal:  Neurosci Lett       Date:  1979-12       Impact factor: 3.046

2.  Assessment in the guinea-pig ileum and mouse vas deferens of benzomorphans which have strong antinociceptive activity but do not substitute for morphine in the dependent monkey.

Authors:  M Hutchinson; H W Kosterlitz; F M Leslie; A A Waterfield
Journal:  Br J Pharmacol       Date:  1975-12       Impact factor: 8.739

3.  Rabbit vas deferens: a specific bioassay for opioid kappa-receptor agonists.

Authors:  T Oka; K Negishi; M Suda; T Matsumiya; T Inazu; M Ueki
Journal:  Eur J Pharmacol       Date:  1981-07-17       Impact factor: 4.432

4.  The irreversible narcotic antagonistic and reversible agonistic properties of the fumaramate methyl ester derivative of naltrexone.

Authors:  A E Takemori; D L Larson; P S Portoghese
Journal:  Eur J Pharmacol       Date:  1981-04-09       Impact factor: 4.432

5.  Unexpected antagonism in the rat vas deferens by benzomorphans which are agonists in other pharmacological tests.

Authors:  M G Gillan; H W Kosterlitz; J Magnan
Journal:  Br J Pharmacol       Date:  1981-01       Impact factor: 8.739

6.  A novel opioid receptor site directed alkylating agent with irreversible narcotic antagonistic and reversible agonistic activities.

Authors:  P S Portoghese; D L Larson; L M Sayre; D S Fries; A E Takemori
Journal:  J Med Chem       Date:  1980-03       Impact factor: 7.446

7.  Some quantitative uses of drug antagonists.

Authors:  O ARUNLAKSHANA; H O SCHILD
Journal:  Br J Pharmacol Chemother       Date:  1959-03

8.  Endogenous opioid peptides: multiple agonists and receptors.

Authors:  J A Lord; A A Waterfield; J Hughes; H W Kosterlitz
Journal:  Nature       Date:  1977-06-09       Impact factor: 49.962

9.  Kinetic parameters of narcotic agonists and antagonists, with particular reference to N-allylnoroxymorphone (naloxone).

Authors:  H W Kosterlitz; A J Watt
Journal:  Br J Pharmacol Chemother       Date:  1968-06

10.  Comparison of binding of [3H]-methionine-enkephalin, [3H]-naltrexone and [3H]-dihydromorphine in the mouse vas deferens and the myenteric plexus and brain of the ginea pig.

Authors:  F M Leslie; H W Kosterlitz
Journal:  Eur J Pharmacol       Date:  1979-07-01       Impact factor: 4.432

View more
  5 in total

1.  Differential effects of selective mu-, kappa- and delta-opioid antagonists on electroshock seizure threshold in mice.

Authors:  H C Jackson; D J Nutt
Journal:  Psychopharmacology (Berl)       Date:  1991       Impact factor: 4.530

2.  Bremazocine is an agonist at kappa-opioid receptors and an antagonist at mu-opioid receptors in the guinea-pig myenteric plexus.

Authors:  A D Corbett; H W Kosterlitz
Journal:  Br J Pharmacol       Date:  1986-09       Impact factor: 8.739

3.  Reversal by beta-funaltrexamine of the antinociceptive effect of opioid agonists in the rat.

Authors:  A G Hayes; M Skingle; M B Tyers
Journal:  Br J Pharmacol       Date:  1986-08       Impact factor: 8.739

4.  Pharmacological characterization of a 7-benzylidenenaltrexone-preferring opioid receptor in porcine ileal submucosa.

Authors:  De Wayne Townsend; David R Brown
Journal:  Br J Pharmacol       Date:  2003-10       Impact factor: 8.739

5.  Alkylation with beta-funaltrexamine suggests differences between mu-opioid receptor systems in guinea-pig brain and myenteric-plexus.

Authors:  T G Franklin; J R Traynor
Journal:  Br J Pharmacol       Date:  1991-03       Impact factor: 8.739

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.